- /
- Supported exchanges
- / US
- / CLDX.NASDAQ
Celldex Therapeutics Inc (CLDX NASDAQ) stock market data APIs
Celldex Therapeutics Inc Financial Data Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Celldex Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Celldex Therapeutics Inc data using free add-ons & libraries
Get Celldex Therapeutics Inc Fundamental Data
Celldex Therapeutics Inc Fundamental data includes:
- Net Revenue: 158 K
- EBITDA: -330 728 000
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Celldex Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -1.02
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celldex Therapeutics Inc News
New
Guggenheim reiterates this biotech stock as a top pick
Investing.com -- Guggenheim has reiterated Celldex Therapeutics as its top pick in the biotechnology sector, citing strong Phase III data and expanding pipeline opportunities for the company's lead dr...
Celldex Stock In Focus After Earnings Loss And Shelf Filing
Celldex Therapeutics reported third quarter 2026 results with a net loss of US$75.56 million and basic loss per share of US$0.96, alongside a universal shelf registration covering common and preferred...
Celldex: Q3 Earnings Snapshot
HAMPTON, N.J. (AP) — HAMPTON, N.J. (AP) — Celldex Therapeutics Inc. (CLDX) on Thursday reported a loss of $75.6 million in its third quarter. The Hampton, New Jersey-based company said it had a l...
Celldex Reports Third Quarter Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. Best-in-disease results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies showed rapid, profound, sustained efficacy supporting barzolvolimab's potential to be a transformat...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.